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ABSTRACT 
Development of therapeutic strategies for tumor-selective delivery of therapeutics, through 
exploitation of the proteolytic tumor phenotype, has significant scope for improvement of 
cancer treatment. ICT2588 is a peptide-conjugated prodrug of the vascular disrupting agent 
(VDA) azademethylcolchicine developed to be selectively hydrolyzed by matrix 
metalloproteinase-14 (MMP-14) within the tumor. In this report, we extend our previous 
proof-of-concept studies and demonstrate the therapeutic potential of this agent against 
models of human colorectal, lung, breast, and prostate cancer. In all tumor types, ICT2588 
was superior to azademethylcolchicine, and was greater or comparable to standard clinically 
used agents for the respective tumor type. Prodrug activation in clinical human lung tumor 
homogenates relative to stability in human plasma and liver was observed, supporting clinical 
translation potential. A major limiting factor to the clinical value of VDAs is their inherent 
cardiovascular toxicity. No increase in plasma von Willebrand factor (vWF) levels, an 
indicator of systemic vascular dysfunction and acute cardiovascular toxicity, was detected 
with ICT2588, thereby supporting the tumor-selective activation and reduced potential of 
ICT2588 to cause cardiovascular toxicity. Our findings reinforce the improved therapeutic 
index and tumor-selective approach offered by ICT2588 and this nanotherapeutic approach.  
 
Keywords: Cancer Therapy; Drug Delivery; Nanotherapeutic; Peptide-conjugate; Matrix 
Metalloproteinase; Vascular Disrupting Agent. 
 
Abbreviations:  MMP, matrix metalloproteinase; MTD, maximum tolerated dose;  NSCLC, 
non-small cell lung cancer; VDA, Vascular disrupting agent; vWF, von Willebrand Factor. 
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INTRODUCTION 
The standard approach for the treatment of advanced or disseminated cancer involves the 
systemic administration of antiproliferative cytotoxic agents. The major drawback to the non-
selectivity of these agents against cancer is dose-limiting toxicity, with the consequent impact 
upon therapeutic efficacy. Over the past decade, in reflection of these limitations, a profound 
change in the direction for cancer drug development has evolved. Based upon the acquisition 
of addiction to specific oncogenic signaling pathways, approaches are now focused toward 
inhibition of specific dysregulated molecular pathways involved in cancer development and 
progression
1, 2. In principle ‘molecularly targeted’ agents are highly selective agents against 
growth and survival of tumor cells, whilst sparing normal cells. However, despite improved 
treatment success and reduced toxicity relative to conventional cytotoxic chemotherapeutics, 
these approaches are not devoid of problems. It is becoming evident that efficacy of these 
such agents is hindered by genetic instability and heterogeneity within the cancer cell 
population, resulting in acquired drug resistance
3
. Furthermore, on- and off-target activities of 
many of these agents against particular ‘normal’ cell populations has led to induction of 
specific toxicities and detrimental physiological effects, and subsequent sub-therapeutic drug 
concentrations in the tumor
2-4
. Therefore the development of new therapeutics to circumvent 
these issues, with improved tumor selectivity, lower systemic toxicity, and limited potential 
for drug resistance is an important trajectory for improved cancer treatment. 
One strategy is to develop agents targeting the tumor phenotype rather than intracellular 
signaling pathways, such as the tumor supporting vasculature or increased proteolytic activity 
of tumors
5-10
. The selective disruption of the established blood supply to tumors is now 
known to be an effective therapeutic strategy, with several vascular disrupting agents (VDAs) 
currently in late stage clinical trial
11-14
. The majority of these agents bind to the colchicine-
binding domain of β-tubulin causing microtubule depolymerisation and consequent 
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morphological changes within endothelial cells
15
. The advantages of VDAs over other cancer 
therapeutics are that they are not required to extravasate from the blood vessel and penetrate 
across several cell layers for their activity, they avoid undesirable acquired drug resistance, 
and they target a fundamental process for survival of all solid tumors 
11-13
. Furthermore, it is 
now well established that the disruption of a single tumor blood vessel results in death of the 
large number of tumor cells it supports 
11, 13, 14
. Additionally, the destabilization of the tumor 
endothelium leads to a temporal enhancement of vascular permeability and consequent drug 
retention, with significant potential for therapeutic enhancement
14-16
. However, it is becoming 
increasingly apparent that the significant therapeutic value for these colchicine-related VDAs 
is compromised by their intrinsic toxicity, particularly cardiac toxicities
17, 18
. Therefore, 
strategies to reduce systemic exposure, increase tumor-selectivity and improve their 
therapeutic index are required. 
Another fundamental issue which impacts upon the success of several current small 
molecule cancer therapies is their limited ability to localize at the tumor site. Many cytotoxic 
drugs demonstrate poor biodistribution in vivo, with tumor doses for common agents such as 
doxorubicin and paclitaxel reported to be around 5-10% of the dose accumulating in healthy 
organs
19, 20
. In addition to reduced efficacy, this also has implications for intrinsic systemic 
toxicity. Therefore, there is a considerable requirement for the development of a new 
generation of anticancer agents, capable of selective localization at the tumor and with 
reduced potential for systemic toxicity. One approach which addresses this need is the 
development of nanotherapeutic agents as tumor-targeted prodrugs, recently termed “cancer 
smartbombs” or “molecular grenades”6, whereby the potent therapeutic entity is masked until 
being activated by exploitation of unique phenotypic differences present in the tumor 
environment 
6, 21, 22
.  
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Harnessing enzymes with elevated or specific activity within the tumor environment to 
convert a non-toxic prodrug into a potent anticancer agent is one approach with significant 
therapeutic scope
6, 8, 21, 23, 24
. A class of enzyme heavily implicated in cancer expansion and 
dissemination, and with clear applicability for prodrug development, are the proteolytic 
enzymes of the tumor degradome
21
. This strategy was recently exemplified through use of the 
tumor-endothelial expressed carboxypeptidase prostate-specific membrane antigen (PSMA) 
for activation of the non-selective toxin thapsigargin, a successful approach which has now 
progressed to phase II clinical trial
6, 7
. Another family of enzymes within the tumor 
degradome with demonstrated potential for tumor-selective prodrug development are the 
matrix metalloproteinases (MMPs)
21
, particularly the membrane-type MMP (MT-MMP) 
subfamily. Of these, the prototypic member MMP-14 (MT1-MMP) has the majority of 
required traits as a prodrug activating target; being pivotal for tumor invasive behavior and 
tumor vascularization
25-30
, presenting as a direct target in the tumor vasculature for prodrug 
activation
25-27, 29
, and having the ability to selectively cleave specific peptide sequences
5, 31
. 
Based on this, we previously designed a MMP-14-targeted nanotherapeutic prodrug, 
ICT2588, comprising the potent VDA, azademethylcolchicine, inactivated through 
conjugation to a cleavable peptide, which was endcapped to prevent non-specific 
exopeptidase degradation (Figure 1)
5, 32
. The peptide sequence integral to this 
nanotherapeutic approach had been rationally developed to be selectively cleaved by MMP-
14
5, 32
. The therapeutic strategy for ICT2588 involves hydrolysis by MMP-14 followed by 
subsequent nonspecific exopeptidase activity to produce azademethylcolchicine selectively 
within the tumor environment
5, 33
. This mechanism was supported in both ex vivo and in vivo 
studies through demonstration of MMP-dependent hydrolysis of ICT2588 followed by rapid 
production of active azademethylcolchicine, with no intermediate peptide-conjugated 
metabolites of ICT2588 detected
5
. In this study we have further evaluated the clinical 
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potential for this MMP-14 activated VDA strategy using a range of clinically relevant human 
solid tumor models and primary surgical samples. A reduced potential for drug-induced 
cardiovascular toxicity with ICT2588 was assessed by development of an assay to measure 
systemic levels of murine von Willebrand Factor (vWF), a validated biomarker of systemic 
vascular dysfunction and acute cardiovascular events
34-37
. 
 
 
 
EXPERIMENTAL SECTION 
Synthesis of ICT2588 
ICT2588 (Figure 1) was synthesized and characterized in-house as a C- and N-terminal 
modified peptide conjugate of azademethylcolchicine (Figure 1), as previously described
32
. 
For in vitro analyses, ICT2588 was prepared as a stock solution in dimethyl sulfoxide 
(DMSO).  
 
Figure 1: Structure of ICT2588 and azademethylcolchicine, indicating the MMP-14 selective 
scissile bond 
Assessment of ICT2588 Activation in Human Clinical Samples ex vivo 
To assess the clinical potential for tumor-selective activation of ICT2588, freshly resected 
and snap frozen specimens of non-small cell lung cancer (NSCLC) and their paired blood 
plasma, as well as human liver were used for this study. Informed patient consent was 
obtained from all patients prior to specimen collection and all patient details were 
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anonymized to ensure confidentiality. All experiments were performed after first obtaining 
consent from the local research and ethics committee according to Medical Research Council, 
UK Regulations. Human tissue samples were stored under the control of Ethical Tissue 
(Bradford, UK) who ensured concordance with regulations required by the UK Human 
Tissue Authority. 
Clinical tumors and liver tissue were homogenized in MMP activity buffer (50 mmol/L 
Tris-HCl (pH 7.6), 1.5 mmol/L NaCl, 0.5 mmol/L CaCl2, 1 μmol/L ZnCl, 0.01 % v/v Brij-35) 
and the resultant supernatants collected by centrifugation. The potential for activation of 
ICT2588 (final concentration 20mol/L) was assessed in human plasma and tumor and liver 
supernatants (equivalent to 100 mg tissue per ml). Over a 90 minute period, reaction aliquots 
were removed, proteins precipitated using acetonitrile and ICT2588 metabolism analyzed by 
LC-MS, as previously described
5
. 
 
Determination of MT-MMP gene expression. 
Assessment of MT-MMP gene expression as determined by quantitative real-time PCR 
(qRT-PCR) was performed as previously described
38
. All primers and fluorogenic probe 
nucleotide sequences were synthesized by Applied Biosystems (Warrington, UK) and had 
been shown previously to be MMP gene specific
38, 39
. The 18S ribosomal RNA gene was 
used as an endogenous control to normalize for any difference in the amount of total RNA in 
each sample, using previously validated procedures
38, 39
. The CT (cycle at which amplification 
entered the exponential phase) was used as an indicator of the level of target RNA in each 
tissue, i.e. a lower CT indicated a higher quantity of target RNA. For data interpretation, 
results were normalized to calibrated curve data for the 18S-rRNA and MMP genes, as 
previously described 
38, 39
. 
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Determination of MMP-14 protein expression. 
Tumor homogenates were prepared as previously described
5
. Equal amounts of protein 
(equivalent to 0.1mg xenograft tissue) were resolved by 10% SDS-PAGE and blotted onto 
Hybond-P membrane (Amersham, UK). Non-specific antibody binding was blocked via 
incubation in 5% ECL blocking reagent (Amersham). The blot was probed with a monoclonal 
antibody to MT1-MMP (MAB3328; Chemicon International) overnight at 4C followed by a 
rabbit anti-mouse horseradish peroxidase (HRP)-conjugated antibody (Dako). Antibody 
reactivity was detected by chemiluminescence using ECL-Plus (Amersham).  
 
Evaluation of Antitumor activity. 
Female Balb/c immunodeficient nude mice (Harlan, Loughborough, UK), between the ages 
of 6 and 8 weeks, were used, Under brief general inhalation anesthesia, 2 to 3 mm
3
 fragments 
of either A549 (non-small cell lung cancer); MCF7 (breast carcinoma); DLD1 (colorectal 
carcinoma); PC3 (prostate adenocarcinoma) or HT1080 (fibrosarcoma) human tumor 
xenograft tumors were implanted subcutaneously in the abdominal flanks. Once tumor 
volumes reached approximately 32 mm
3
 (as measured by calipers) mice were randomized 
into groups (n=8) and received ICT2588 at 75 mg/kg or solvent control (10% DMSO/arachis 
oil) via intraperitoneal (i.p.) administration. For comparison to other chemotherapeutics, 
tumor-bearing mice received either azademethylcolchicine at 15 mg/kg (molar equivalent 
dose to 75mg/kg ICT2588), doxorubicin at 10 mg/kg intravenously (i.v.), 5-fluorouracil at 
100 mg/kg i.p., Paclitaxel at 20 mg/kg i.p., or combretastatin-A4 phosphate (CA4P) at its 
maximum-effective dose of 150 mg/kg i.p. Tumor volume (measured by calipers) and animal 
body weight were recorded daily for up to 25 days. Tumor growth data is presented as the 
ratio of the mean tumor volume on individual days relative to the tumor volume on the initial 
day of treatment (day 0), with the mean relative tumor volume on day 0 being 1.0. Mann-
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Whitney U tests were conducted to determine the statistical significance of any differences in 
growth rate (based on tumor volume doubling time) between control and treated groups. 
Throughout the study, all mice were housed in air-conditioned rooms in facilities approved 
by the Home Office to meet all current regulations and standards of the United Kingdom. All 
procedures were carried out under a United Kingdom Home Office Project License, 
following UK National Cancer Research Institute Guidelines for the Welfare of Animals 
(UKCCCR) guidelines
40
. 
 
 
Measurement of systemic levels of von-Willebrand Factor (vWF) 
Mice (Female Balb/c immunodeficient) were injected with either azademethylcolchicine 
(30 mg/kg i.p.), ICT2558 (150 mg/kg i.p.), doxorubicin (10mg/kg i.v.), or solvent control. At 
4, 24 hours (all drugs) and 48 hours (ICT2588) post-treatment mice were sacrificed, blood 
collected into heparinized tubes, centrifuged at 2,000 x g for 10 minutes, and the resultant 
plasma aliquoted and stored at -80ºC until use. Normal and human tissues were subsequently 
removed and also stored at -80ºC. A purified vWF protein standard (from human plasma) 
was obtained from the National Institute for Biological Standards and Control (NIBSC; 
Hertfordshire, UK), supplied at a concentration 11 IU/ml. 
Microplate wells (Nunc Maxisorp 96-well; Thermo Scientific, UK) were coated with 100µl 
of purified sheep anti-vWF capture antibody (AB11713; Abcam, UK) diluted 1:500 in 
phosphate buffered saline (PBS; 10mM, pH 7.2), covered and incubated overnight at 4ºC. 
Plates were washed three times in PBS / 0.05% Tween 20 using an automated platewasher 
(WellWash, Thermo Scientific), and non-specific binding blocked via incubation in PBS/1% 
BSA for 60 minutes at room temperature (RT). The vWF standard was serially diluted in 
PBS, creating a concentration range of 0.002-0.12 IU/ml, and murine plasma samples were 
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diluted 1:2 and 1:8 in PBS. After washing, 100 µl of each standard and sample were added to 
the plate, with PBS alone added as a blank control. Plates were incubated for 60 minutes at 
RT, with gentle agitation, and washed. Rabbit anti-vWF horseradish peroxidase-conjugated 
antibody (P0226; Dako) was added to each well (100µl) at a dilution of 1:400 in PBS, and the 
plate sealed and incubated for 60 minutes at RT, with gentle agitation. Wells were washed, 
100µl TMB solution (Sigma-Aldrich) added to each well, and the reaction stopped after 5 
minutes by addition of 100µl TMB stop solution (2 M H2SO4; Sigma-Aldrich). After a 
further 5 minutes of color development, absorbance of each well was measured at 450 nm, 
with correction at 550 nm, using a Multiskan EX platereader (Thermo Life Sciences). A 
calibration curve was generated using the vWF protein standards, and sample values were 
interpolated into this curve to obtain concentration values. Data were analyzed using SPSS, 
and mean differences considered statistically significant at the P < 0.05 level. 
 
RESULTS 
 
 
Figure 2: Selective activation of ICT2588 in human non-small cell lung cancer (NSCLC). 
(A) Expression of MMP-14 mRNA in two clinical NSCLC tumor biopsies as measured by 
quantitative RT-PCR, calculated relative to a calibration sample
38
. (B) Metabolism of 
11 
 
ICT2588 by clinical NSCLC biopsies relative to plasma from the same patients, and (C) 
metabolism of ICT2588 in homogenates of human liver relative to murine liver and the 
MMP-14-expressing HT1080 tumor model. For the metabolism studies, ICT2588 was 
quantified using liquid chromatography-mass spectrometry (LC-MS) and the degree of 
proteolytic metabolism indicated by the concentration of ICT2588 remaining over time, as 
previously described
5
. 
Metabolites detected by LCMS and expressed as concentration of ICT2588 remaining. 
Selective metabolism of ICT2588 in human clinical NSCLC relative to normal tissue 
The elevated expression of MT-MMPs in non-small cell lung cancer (NSCLC) relative to 
associated normal lung tissue, and a strong correlation between MMP-14 gene expression and 
proteolytic activity is previously reported by our group
38
. In order for ICT2588 to be a viable 
clinical therapeutic option, it must show activation in tumor tissue, limited activation in non-
diseased tissue and the potential for systemic pharmacological stability. Metabolism of 
ICT2588 was studied ex vivo using homogenates of two clinical samples of NSCLC and their 
respective blood plasma. In both tumor samples MMP-14 expression was elevated (Figure 
2A) and ICT2588 was metabolized rapidly (t½ = 11.4 minutes and 23.2 minutes, respectively 
(Figure 2). In contrast, ICT2588 metabolism was minimal in plasma samples from these 
patients (t½ > 90 minutes; Figure 2B) and human and mouse liver homogenates (Figure 2C).  
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Figure 3: Antitumor activity of ICT2588 against human (A) NSCLC and (B) Colorectal 
tumor models. ICT2588 inhibits tumor growth to a greater extent than an equimolar 
concentration of azademethylcolchicine (active metabolite of ICT2588) and comparable to 
standard agents; doxorubicin for NSCLC (A) and Paclitaxel and 5-Fluorouracil for colorectal 
tumors (B). Mice were treated with a single intraperitoneal dose of ICT2588 (75 mg/kg; 
maximum effective dose, equivalent to 50% maximum deliverable dose). Mice bearing A549 
NSCLC tumors were administered an equimolar dose of azademethylcolchicine (15 mg/kg, 
i.p) or doxorubicin (10mg/kg, i.v.), and those bearing DLD1 colorectal tumors were 
administered a single dose of paclitaxel (20 mg/kg, i.p) or 5-Fluorouracil (10mg/kg, i.p.). The 
tumor growth delay is defined as time taken for doubling of tumor volume relative to control, 
denoted in brackets in the legend of each figure. 
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Treatment with ICT2588 was comparable to, or an improvement upon current clinically used 
therapeutics. Against the A549 NSCLC tumor model, ICT2588 produced a significantly 
greater tumor response than azademethylcolchicine (active metabolite of ICT2588), and a 
similar response to that of doxorubicin (Figure 3A). In the colorectal DLD-1 tumor model, 
therapeutic response to ICT2588 was comparable to that of Paclitaxel and 5-Fluorouracil 
(Figure 3B). 
Against the PC3 prostate xenograft model, VDAs resulted in a significant growth delay 
compared with vehicle-treated control (P < 0.01; Figure 4). The antitumor effect of a single 
dose administration was significantly greater for ICT2588, with a tumor growth delay of 9.3 
days relative to 3.1 (P < 0.05) and 1.2 days (P < 0.01) for its’ active metabolite 
(azademethylcolchicine) and Combretastatin-A4 Phosphate (CA4P), respectively (Figure 4). 
In all tumor models, administration of the various treatments did not cause any significant 
loss in mouse body weight (≤15%; data not shown). 
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Figure 4: Antitumor activity of Vascular Disrupting Agents against human PC-3 prostate 
tumor model. Administration of a single intraperitoneal dose of ICT2588 results in a 
significantly greater inhibition of PC-3 tumor growth compared to the active metabolite 
(azademethylcolchicine) at equimolar concentrations, or Combretastatin-A4-Phosphate at 
150mg/kg. The tumor growth delay is defined as time taken for doubling of tumor volume 
relative to control, denoted in brackets in the legend of each figure. 
 
Activity of ICT2588 against MCF-7 human breast carcinoma in vivo 
A lack of activity of ICT2588 against an MMP-14 negative cell line (MCF7) in vitro had 
been demonstrated in our previous study, consistent with a requirement for MMP-14 
involvement in ICT2588 activation
5
. However, in contrast to MCF7 cells grown in vitro, the 
presence of MMP-14 was detectable in ex vivo MCF7 tumor homogenates
5
 (Figure 5). 
Whereas human MMP-14 mRNA was undetectable in the MCF7 xenograft model
5
, moderate 
expression of murine MMP-14 was detected (Figure 5). 
Administration of ICT2588 to mice bearing MCF7 tumors produced a significant tumor 
response compared with vehicle-treated controls, with a growth delay of 7.3 days. This is 
much greater than an equimolar dose (15 mg/kg) of the active metabolite 
(azademethylcolchicine) which produced a considerably diminished growth delay of 2.0 days 
(Figure 5B). 
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Figure 5: The role of the tumor microenvironment in activity of ICT2588. Although MCF-7 
xenografts demonstrate negligible expression of human MMP-14 mRNA, the levels of 
murine MMP-14 are similar to those of the HT1080 xenograft (A). The MMP-14 protein 
expressed by the murine stromal and endothelial cells (B) is sufficient to activate ICT2588 
and result in significant inhibition of MCF7 tumor growth compared to 
azademethylcolchicine at equimolar concentrations. Mice were treated with a single 
intraperitoneal dose of ICT2588 or azademethylcolchicine and tumor size determined daily. 
The tumor growth delay is defined as time taken for doubling of tumor volume relative to 
control, denoted in brackets in the legend of each figure. 
 
Post-treatment changes in plasma vWF levels, as an indicator of cardiovascular effects. 
Systemic levels of vWF were determined as an indicator of drug-induced detrimental 
effects upon the cardiovascular system, as previously reported
34-37
. Using vWF standards the 
ELISA assay was linear between 2.0x10
-3
 and 0.03 IU/ml (R
2
 = 0.975), with an inter-assay 
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variability of <5% (Data not shown). The dilution-corrected concentration of plasma vWF in 
vehicle-treated control mice was between 0.07 and 0.10 IU/ml monitored at 4, 24 and 48 hrs 
(Table 1). This was comparable to that detected in non-treated mice plasma (Table 1). 
Administration of ICT2588 did not result in a significant increase in circulating levels of 
vWF at 24 hours over that detected in vehicle-treated controls (P = 0.6; Table 1 and Figure 
6). In contrast, azademethylcolchicine at an equimolar dose caused a significant elevation in 
plasma vWF levels after 24 hours (P < 0.05; Table 1 and Figure 6). No increase in plasma 
vWF levels were detected following exposure to the chemotherapeutic agent doxorubicin 
(Figure 6). Additionally, no delayed rise in vWF levels was observed with the prodrug 
ICT2588, as at 48 hours the plasma vWF concentration was not significantly different to 
vehicle treated control mice (P = 0.50; Table 1). 
 
Figure 6: Levels of von-Willebrand (vWF) factor in mouse plasma following drug treatment. 
Mice were treated with ICT2588, azademethylcolchicine (a-dm-Colch), or doxorubicin and 
plasma vWF levels measured 24 h post-treatment. Graph represents mean values from 3 mice 
± standard error. * P<0.05 relative to control. 
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Table 1. Plasma levels of von-Willebrand factor (vWF) following drug administration
2
. 
 Plasma concentration of vWF (IU/ml) 
Drug Treatment 4 hrs 24 hrs 48hrs 
Control  0.09 ± 0.023 0.10 ± 0.031 0.07 ± 0.021 
Azademethylcolchicine 0.12 ± 0.016 0.18 ± 0.016 n.d. 
ICT2588 0.12 ± 0.017 0.12 ± 0.015 0.09 ± 0.020 
Doxorubicin 0.10 ± 0.022 0.11 ± 0.016 n.d. 
 
DISCUSSION 
Drug-induced disruption of established tumor vasculature is a promising therapeutic 
strategy, with several colchicine based VDAs currently in late-stage development
11-13
. 
However, the off-target toxicities of these agents, primarily against the cardiovascular 
system, has limited their clinical progression
17, 18
. We previously reported a therapeutic 
strategy to overcome the limitations outlined above, which exploits the therapeutic potential 
of VDAs and exploits the tumor phenotype. The therapeutic ‘smartbomb’, ICT2588, was 
designed to selectively deliver the VDA, azademethylcolchicine, to the tumor through 
activation by membrane-type MMPs (MT-MMPs) endopeptidases specifically located within 
the tumor microenvironment
5
. 
ICT2588 illustrates how harnessing of the tumor degradome to convert an inactive 
‘smartbomb’ into its active chemotherapeutic metabolite, has shown significant promise5. 
Elevated expression of membrane-type MMPs (MT-MMPs) has been demonstrated in many 
tumor types, both preclinically and clinically
5, 25, 27, 30, 38
, with a direct relationship between 
genetic expression of MMP-14 (MT1-MMP) and its enzyme activity
38
, strongly supporting 
these endopeptidases as tumor-selective activators of therapeutics
5, 21, 38
. Our previous study 
demonstrated the viability for MMP-14 activated tumor ‘smartbombs’ and illustrated proof-
of-concept,  using a human fibrosarcoma xenograft model known to express very high levels 
                                                 
2
 Values are dilution-corrected and represent the mean of 3 independent experiments ± 
standard error 
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of MMP-14
5, 38
. Together with the pivotal role MMP-14 plays in tumor expansion and 
dissemination
26, 29, 30
, the implication is that this technology would be applicable to the 
treatment of all solid vascularized tumors. This is demonstrated in this study by the 
significant antitumor responses and the superior activity of ICT2588 relative to equimolar 
doses of its active metabolite (azademethylcolchicine), against NSCLC, colorectal, breast and 
prostate tumor models. The importance of the tumor stroma and vasculature in the therapeutic 
mechanism is exemplified with the MCF7 breast cancer model. These cells are negative for 
human MMP-14 in vitro and in vivo, but have detectable murine MMP-14 levels in vivo, 
representing expression within tumor stroma and neovasculature, as previously indicated
25, 27, 
41, 42
. The significant growth delay observed following administration of ICT2588 indicates 
that in addition to expression of MMP-14 within the tumor mass, the presence of MMP-14 
within the tumor microenvironment provides a further dimension to the therapeutic response 
of this approach. This indication of an integral role for the tumor microenvironment in 
activation of ICT2588 is also beneficial in terms of cancer therapy, as it effectively permits 
circumvention of downregulation of MMP-14 within the tumor mass as a mechanism of 
acquired drug resistance and any consequent reduction in therapeutic response.  
An important indication for any developmental therapeutic is its clinical potential. The 
rapid metabolism of ICT2588 in homogenates of clinical specimens of NSCLC ex vivo, 
whilst remaining relatively stable in corresponding plasma samples and homogenates of 
human liver gives a strong indication for clinical translation of our therapeutic approach.  
Treatment with ICT2588 is comparable to or an improvement on standard clinically 
applicable chemotherapeutics. The concentration of ICT2588 administered was previously 
shown to result in its maximal pharmacodynamics effect of vasculature shutdown, but to be 
significantly lower than its maximum tolerated dose (MTD; >150 mg/kg)
5
. Such a beneficial 
effect is a common attribute of colchicine-like VDAs, consistent with their effect upon the 
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tumor vasculature
5, 12, 13, 15
. One significant advantage of targeting a VDA, rather than an 
entity requiring direct interaction with tumor cells, is the proximity and accessibility of the 
cellular target. Whereas other smartbombs delivering tumor-cell focused agents must 
penetrate from the vasculature to instigate their effect, ICT2588 after being activated does not 
require such diffusion or transport for maximal activity as it acts upon the genetically stable 
tumor endothelium. Consequently, any activity against tumor cells is as an additional 
secondary or ‘bystander’ effect, rather than as a primary mode of action. A limitation to the 
use of VDAs is the persistence of a ‘viable rim’ of tumor cells at the periphery of the tumor 
mass, a factor resulting from these particular cells being supported by the normal established 
vasculature rather than the VDA-sensitive neovasculature
5, 11-13, 15
. Consequently, clinical 
VDA therapeutic regimens are rationalized to require co-treatment with agents to target the 
tumor cells in this rim
11, 13
. Our ability to effect tumor cures with ICT2588 and doxorubicin 
combination treatment is supportive of this
4e
. The superior response observed in several 
studies with co-treatment of a VDA and antiproliferative agent, as opposed to either agent 
alone, is likely a result of a VDA-induced temporal enhanced permeability and retention 
(EPR) effect within the tumor as a response to destabilization of the tumor endothelium
11, 14, 
16
, causing an enhancement of drug targeting and retention at the tumor site. Existence of this 
beneficial activity of ICT2588 is supported by the development of an MMP-14 activated 
theranostic agent, indicated by prolonged retention of the imaging nanoparticle within the 
tumor mass
33
.  
In the present study we evaluated ICT2588 against azademethylcolchicine and 
combretastatin-A4-phosphate (CA4P), two systemically active VDA’s. ICT2588 was three-
fold and seven-fold more active in terms of growth delay relative to azademethylcolchicine 
and CA4P respectively, indicating this tumor-activated molecule offers a benefit consistent 
with dose-exposure intensification previously reported for ICT2588 
5
. 
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The reduced systemic exposure offered by ICT2588 through tumor-selective activation 
effectively reduces the likelihood of cardiovascular toxicities commonly associated with 
VDA therapy
13, 17, 18
. Such an assumption is based on previous studies wherein levels of 
azademethylcolchicine were below the level of detection in the circulation or cardiac tissue 
following ICT2588 administration
5
. However, a lack of detectable active agent does not 
account for effects upon endothelial and cardiovascular function. Increased plasma levels of 
von Willebrand factor (vWF) is a validated biomarker indicative of systemic vascular 
dysfunction and predictive of acute cardiovascular events
34-36
. Importantly the absence of 
raised vWF following ICT2588 administration to mice suggests that our targeted VDA is not 
overtly cardiotoxic, a problem commonly associated with VDA therapy
13, 17, 18
. Post ICT2588 
treatment, levels of vWF were no greater than observed with the antiproliferative agent 
doxorubicin. Although doxorubicin is identified with clinical cardiotoxicity, this is a 
consequence of cumulative chronic drug exposure
43
. Acute exposure to doxorubicin is not 
associated with cardiovascular events, as previously reported in a preclinical study of breast 
cancer therapy
37
. In summary these results support our previous study which shows that 
tumor-selective activation of ICT2588 is producing an increased therapeutic index, not only 
due to dose enhancement at the tumor site, but also because of reduced systemic toxicity. 
In conclusion, the activity of ICT2588 against colorectal, lung, breast and prostate tumors 
supports its widespread therapeutic potential and activation in clinical tumors associated with 
MMP-14 expression. This, in combination with lower and evidential reduction in potential 
for inducing cardiovascular events provides strong justification for progression of ICT2588 
as a tumor-selective VDA. 
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